Evoke Q3 financial results: 6 notes

Evoke Pharma, which focuses on treating gastrointestinal diseases, released its third quarter financial results Nov. 10. 

Six notes:

1. For the third quarter of 2021, selling, general and administrative expenses were about $2.6 million, compared to about $1.9 million for the third quarter of 2020. 

2. Net loss was $2 million, or $.06 per share, compared to $2.1 million during the same period last year. 

3. Net product sales were about $930,000, compared to $237,000 in the second quarter of this year.

4. Research and development expenses totaled about $100,000 for the third quarter of this year, compared to $200,000 for the same period last year. 

5. As of Sept. 30, Evoke's cash and cash equivalents were about $11.1 million

6. The company had 84 new prescribers added in the third quarter of this year.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast